30.56

1.13% -0.35

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is currently priced at $30.56, with a 24-hour trading volume of 217.55K. It has seen a -1.13% decreased in the last 24 hours and a -7.42% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $32.05 pivot point. If it approaches the $29.71 support level, significant changes may occur.

Previous Close:

$30.91

Open:

$30.42

24h Volume:

217.55K

Market Cap:

$1.75B

Revenue:

$582.02M

Net Income/Loss:

$128.85M

P/E Ratio:

12.42

EPS:

2.46

Net Cash Flow:

$219.08M

1W Performance:

+4.55%

1M Performance:

-7.42%

6M Performance:

+24.63%

1Y Performance:

-6.72%

1D Range:

$29.62

$30.63

52W Range:

$18.61

$39.27

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1201)

Industry

Biotechnology (682)

Phone

484 539 9800

Address

630 West Germantown Pike, Suite 215, Plymouth Meeting

Employee

150

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

HRMY's Discussions on Twitter

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript

The Motley Fool

Key Takeaways From Harmony Biosciences Analyst Ratings

Benzinga

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

GlobeNewswire Inc.

Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data

Harmony Biosciences Holdings Inc (HRMY) Revenue 2024

HRMY reported a revenue (TTM) of $582.02 million for the quarter ending December 31, 2023, a +32.93% rise year-over-year.

Harmony Biosciences Holdings Inc (HRMY) Net Income 2024

HRMY net income (TTM) was $128.85 million for the quarter ending December 31, 2023, a -28.99% decrease year-over-year.

Harmony Biosciences Holdings Inc (HRMY) Cash Flow 2024

HRMY recorded a free cash flow (TTM) of $219.07 million for the quarter ending December 31, 2023, a +110.06% increase year-over-year.

Harmony Biosciences Holdings Inc (HRMY) Earnings per Share 2024

HRMY earnings per share (TTM) was $2.12 for the quarter ending December 31, 2023, a -28.62% decline year-over-year.

Harmony Biosciences Holdings Inc Stock (HRMY) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 15 '24	Option Exercise	8.22	11,979	98,467	11,979
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 15 '24	Sale	32.00	11,979	383,328	0
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 08 '24	Option Exercise	8.22	194	1,595	194
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 08 '24	Sale	32.00	194	6,208	0

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.